Portions of this research were presented as posters: Boonen S, Klemes A, Zhou X, Pack S, Delmas PD. Patients treated with risedronate have a fracture risk similar to patients 20 years younger in age. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research; September 16–19, 2007; Honolulu, Hawaii. Lindsay R, Zhou X, James R, Boonen S. Non-vertebral fracture risk of risedronate treated patients is similar to that of untreated patients 10 years younger. IBMS_09. Presented at the 2nd Joint Meeting of the International Bone & Mineral Society and the Australian & New Zealand Bone & Mineral Society, March 21–25, 2009, Syndey, Australia. Lindsay R, Zhou X, James R, Boonen S. Non-vertebral fracture risk of risedronate treated patients is similar to that of untreated patients 10 years younger. Presented at the National Osteoporosis Foundation's 8th International Symposium on Osteoporosis; April 1–5, 2009; Washington, DC.
Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies
Article first published online: 22 MAR 2010
© 2010, Copyright the Authors. Journal compilation © 2010, The American Geriatrics Society
Journal of the American Geriatrics Society
Volume 58, Issue 4, pages 658–663, April 2010
How to Cite
Boonen, S., Klemes, A. B., Zhou, X. and Lindsay, R. (2010), Assessment of the Relationship Between Age and the Effect of Risedronate Treatment in Women with Postmenopausal Osteoporosis: A Pooled Analysis of Four Studies. Journal of the American Geriatrics Society, 58: 658–663. doi: 10.1111/j.1532-5415.2010.02763.x
- Issue published online: 1 APR 2010
- Article first published online: 22 MAR 2010
- fracture risk;
OBJECTIVES: To quantify the effect of age on the incidence of osteoporosis-related fractures and of risedronate treatment on fracture risk in different age groups in women with postmenopausal osteoporosis.
DESIGN: Data from four randomized, double-blind, placebo-controlled, Phase III studies were pooled and analyzed.
PARTICIPANTS: The analysis population (N=3,229) consisted of postmenopausal women with osteoporosis as determined on the basis of prevalent vertebral fractures, low bone mineral density (BMD), or both.
INTERVENTION: Patients had received risedronate 5 mg daily or placebo for 1 to 3 years.
MEASUREMENTS: The endpoints of interest were the incidence of osteoporosis-related fractures, clinical fractures, nonvertebral fractures, and morphometric vertebral fractures. The effect of age on fracture risk and treatment benefit was examined using Cox regression models with age and treatment as explanatory variables. The 3-year fracture risk was estimated for patients in each treatment group at a given age.
RESULTS: Irrespective of treatment, fracture risks were greater in older patients (P<.001). On average, for every 1-year increase in age, a patient's risk for osteoporosis-related fracture increased 3.6% (95% confidence interval=2.3–5.0%). Irrespective of age, risedronate treatment reduced fracture risk 42%. Risedronate-treated patients had fracture risks similar to those of placebo-treated patients 10 to 20 years younger.
CONCLUSION: Patients treated with risedronate have a significantly lower fracture risk, similar to that of untreated patients 10 to 20 years younger.